# OnCo record pancreatitis-and-raised-pancreatic-enzymes-on-targeted-drugs (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/pancreatitis-and-raised-pancreatic-enzymes-on-targeted-drugs/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "pancreatitis-and-raised-pancreatic-enzymes-on-targeted-drugs" ;
  schema:name "Pancreatitis and raised pancreatic enzymes on asciminib, ponatinib, nilotinib and bosutinib: monitoring, hold and stop rules"@en ;
  schema:alternateName "raised lipase on TKIs"@en, "raised amylase on TKIs"@en, "lipase monitoring on asciminib"@en, "lipase monitoring on ponatinib"@en, "pancreatitis on ponatinib"@en, "pancreatitis on nilotinib"@en, "pancreatic toxicity of BCR::ABL1 inhibitors"@en, "pancreatic enzyme elevation on CML treatment"@en ;
  schema:description "Asciminib, ponatinib, nilotinib and bosutinib can raise two pancreas enzymes in the blood, lipase and amylase, and can sometimes inflame the pancreas (pancreatitis). Blood tests look for this: monthly on asciminib and nilotinib, and every 2 weeks for the first 2 months on ponatinib. Tell your team right away about sudden or severe stomach pain, feeling sick or being sick."@en ;
  schema:url <https://onco.cc/protocols/pancreatitis-and-raised-pancreatic-enzymes-on-targeted-drugs/> ;
  schema:dateModified "2026-11-18"^^xsd:date ;
  onco:related <https://onco.cc/protocols/raised-liver-enzymes-on-targeted-anticancer-drugs/>, <https://onco.cc/protocols/raised-lipids-and-weight-gain-on-lorlatinib-bexarotene-and-elacestrant/> ;
  onco:drugs <https://onco.cc/drugs/asciminib/>, <https://onco.cc/drugs/ponatinib/>, <https://onco.cc/drugs/nilotinib/>, <https://onco.cc/drugs/bosutinib/> ;
  onco:terms <https://onco.cc/terms/ctcae-grading/>, <https://onco.cc/terms/dose-modification/> .
